Entering text into the input field will update the search result below

Takeda Pharmaceutical's (TKPHF) CEO Christophe Weber on Q3 2018 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Takeda Pharmaceutical Co Ltd (OTCPK:TKPHF) Q3 2018 Earnings Conference Call February 1, 2019 3:00 AM ET

Company Participants

Costa Saroukos – Chief Financial Officer

Takashi Okubo – Global Head-Investor Relations

Christopher Morabito – President Business R&D-Head

Rajeev Venkayya – Vaccine Business Unit President

Christophe Weber – Representative Director, Chief Executive Officer

Conference Call Participants

Atsushi Seki – UBS

Kazuaki Hashiguchi – Daiwa Securities

Hidemaru Yamaguchi – Citigroup

Fumiyoshi Sakai – Crédit Suisse

Joseph Cairnes – Deutsche Bank

Shinichiro Muraoka – Morgan Stanley

Costa Saroukos

Hello, everyone. This is Costa Saroukos speaking. Thank you for joining the call today on Takeda's Quarter Three Results. I'm very pleased to report that our strategic focus and superior execution continues to drive robust year-to-date performance. But before going into details on the quarter three results, let me quickly recap on our disclosure time lines going forward.

Please turn to Slide 3. Slide 3 is aligned with the time line we showed in the presentation to announce the completion of the Shire acquisition. As a reminder, the deal was completed on January 8, 2019. Today, February 1, I will be presenting the Takeda fiscal year 2018 quarter three results, meaning legacy Takeda performance from April to December 2018. Later in February, Takeda will publish the January to December 2018 results for the legacy Shire business on our website.

Since the deal closed three weeks ago, we have been working closely with our new colleagues on bringing the two companies together, and we will have comprehensive business planning discussions in the coming weeks. Parallel to this, we are working with our auditors on the purchase price allocation of the deal. This will confirm how assets will be allocated on the Takeda balance sheet and what impact that allocation will have on our reported P&L. Once we have completed this process in April, we

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.